Pfizer Australia and BioNTech SE today announced that the Therapeutic Goods Administration (TGA) have authorised the companies’ XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) in individuals 5 years and older.
Study Offers Clues for Avoiding RMD Flares After COVID Vaccination
Predicting which people with inflammatory rheumatic musculoskeletal diseases (I-RMDs) may experience flares after COVID-19 vaccination just got a bit easier, thanks to a new analysis